|
A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma Clinical research trials and A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma. A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma clinical trial. Participants frequently get the best healthcare available for their A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma  A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma
A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV seropositivity. - Biopsy-proven mucocutaneous Kaposi's sarcoma with fewer than 50 skin lesions and measurable disease. - No active opportunistic infection. NOTE: - Patients with CD4 count >= 200 cells/mm3 must have no prior opportunistic infection, as well as no active opportunistic infection. - Life expectancy of at least 24 weeks. - Stable weight (+/- 2 kg) by 28 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Other active malignancies (except basal cell carcinoma of the skin and in situ cervical cancer). - Known or suspected hypersensitivity to benzodiazepines. - Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease as determined by the investigator. - Ongoing diarrhea (> two liquid stools per day). - Grade 2 or worse signs and symptoms of AIDS Dementia Complex. - Alteration of mental status that may interfere with study compliance. Concurrent Medication: Excluded: - AZT, ddI, or ddC. - Experimental antiretrovirals. - Biologic response modifiers or immunomodulating agents (e.g., interferon). - Colony stimulating factors (erythropoietin, GM-CSF, G-CSF). - Ganciclovir. - Foscarnet. - H-2 antagonists (cimetidine, ranitidine, famotidine, nizatidine). - Omeprazole. - Benzodiazepines. - Any other investigational compound. - Ongoing systemic treatment with corticosteroids (other than replacement therapy for adrenal insufficiency or short-term therapy of no more than 28 days for bronchial asthma). - Cytotoxic chemotherapy (systemic and local). - Drugs known to cause systemic toxicity, if avoidable (e.g., myelosuppressive, hepatotoxic, nephrotoxic, or neurotoxic drugs). - Paromomycin sulfate. - Chronic suppressive therapy for CMV and/or MAI. Patients with the following prior condition are excluded: History of serious adverse reactions to benzodiazepines. Prior Medication: Excluded: - Interferons or immune modulators within 4 weeks prior to study entry. - Prior systemic cytotoxic chemotherapy (patients with CD4 counts >= 200 cells/mm3 only). - Benzodiazepines within 14 days prior to study entry. - Intralesional chemotherapy for Kaposi's sarcoma within 2 weeks prior to study entry. - Therapy with antiretroviral drugs (including AZT, ddI, ddC, d4T) or investigational drugs within 14 days prior to study entry. Localized radiotherapy. Radiotherapy (other than localized). Active drug or alcohol abuse.
Total Enrollment:
Location and Contact Information:
CARE Ctr / UCLA Med Ctr
Los Angeles, California, 900951793
United States
New England Deaconess Hosp
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: 128A;
Study Start Date:
Record last reviewed: December 1993
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002314
Other Hiv Infections Studies:
1. Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
2. A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
3. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies
4. A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
5. A Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
Related Studies:
Other HIV Infections Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma
|
|
|
|
|
|
|
|
